Skip to main content
SpringerLink
Log in

Primary Plasma Cell Leukemia: Identity Card 2016

  • Leukemia (JP Dutcher, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Primary plasma cell leukemia (PPCL) is an aggressive and rare variant of multiple myeloma (MM), characterized by peculiar adverse clinical and biological features. Though the poor outcome of PPCL has been slightly improved by novel treatments during the last 10 years, due to the limited number of available studies in this uncommon disease, optimal therapy remains a classic unmet clinical need. Anyway, in the real-life practice, induction with a bortezomib-based three-drug combination, including dexamethasone and, possibly, lenalidomide, or, alternatively, thalidomide, cyclophosphamide, or doxorubicin, is a reasonable first-line option. This approach may be particularly advisable for patients with adverse cytogenetics, hyperleucocytosis, and rapidly progressive disease, in whom a fast response is required, or for those with suboptimal renal function, where, however, lenalidomide should be used with caution until renal activity is restored. In younger subjects, leukemia/lymphoma-like more intensive regimens, including hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone or continue-infusion cisplatin, doxorubicin, cyclophosphamide, and etoposide, may be also combined with bortezomib +/- thalidomide. Treatment must be started immediately after a diagnosis of PPCL is made to avoid the risk of irreversible disease complications and, in such a context, the prevention of tumor lysis syndrome is mandatory. In patients eligible for autologous stem cell transplantation (AuSCT), other alkylating agents, in particular melphalan, should be initially avoided in order to allow adequate collections of CD34+ peripheral blood stem cells (PBSC). A combination of lenalidomide and dexamethasone may be a valuable alternative option to manage older or unfit patients or those with slower disease evolution or with signs of neuropathy, contraindicating the use of bortezomib. Patients not suitable for transplant procedures should continue the treatment, if a response occurs and if tolerated, considering the possibility of a prolonged maintenance therapy. AuSCT should be pursued in all eligible patients less than 65 years old who achieve a significant response after a short course of induction treatment. PBSC collection should reach a threshold of at least 5 × 106 CD34+ PBSC/kg using cyclophosphamide plus G-CSF and adding the mobilizing agent plerixafor, if necessary. High-dose melphalan (HDM) (200 or 140 mg/m2, according to age and renal function) remains the preferable conditioning regimen. A second AuSCT should be always considered, even in patients achieving complete response (CR) after the first AuSCT, as the short progression-free survival (PFS) generally seen in PPCL suggests the persistence of a relevant burden of residual disease; this provides a strong rationale for the use of post-transplantation therapies in PPCL to improve depth of response, to maintain remission, and, possibly, to increase survival, though consolidation and/or maintenance strategies with novel agents, whose efficacy has been well demonstrated in MM, have not been still extensively evaluated in PPCL. The search of a suitable donor should start as soon as possible and an allogeneic stem cell transplant (AlloSCT) with a myeloablative conditioning (MAC) regimen discussed with younger patients responsive to induction therapy and with poor prognostic parameters at diagnosis. A sequence of AuSCT followed by reduced intensity conditioning (RIC) or non-myeloablative (NMA) AlloSCT may be considered in selected cases. Salvage therapies for relapsed/refractory disease, especially using new drugs not employed at diagnosis, are sometimes effective in the short term, but a rapid relapse is still generally the rule; AlloSCT in relapsed and eligible patients with sensitive disease after salvage treatments is, therefore, recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973–2003. Cancer Causes Control. 2008;19:841–58.

    Article  PubMed  Google Scholar 

  2. Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer. 2009;115:5734–9.

    Article  PubMed  Google Scholar 

  3. Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124:907–12. The most important and updated registry study for PPCL, which demonstrates a moderate, but significant improvement in survival after the introduction of novel agents as first line treatment in the clinical practice.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974;133:813–8.

    Article  CAS  PubMed  Google Scholar 

  5. FernándezdeLarrea C, Kyle RA, Durie BGM, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780–91. An extensive review with international consensus on diagnostic and response criteria and treatment recommendations for PCL.

    Article  Google Scholar 

  6. Jelinek T, Kryukov F, Rihova L, Hajek R. Plasma cell leukemia: from biology to treatment. Eur J Haematol. 2015;95:16–26. The most recent and updated review of clinical and biological features of PCL.

    Article  PubMed  Google Scholar 

  7. An G, Qin X, Acharya C, Xu Y, Deng S, Shi L, et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol. 2015;94:257–64.

    Article  PubMed  Google Scholar 

  8. Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014;28:2060–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cha CH, Park CJ, Huh JR, Chi HS, Suh CW, Kang YK. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol. 2007;118:178–82.

    Article  PubMed  Google Scholar 

  10. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, et al. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011;11:507–11.

    Article  PubMed  Google Scholar 

  12. Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259–72.

    Article  PubMed  Google Scholar 

  13. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. Br J Haematol. 1994;88:754–9.

    Article  CAS  PubMed  Google Scholar 

  14. García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032–7.

    PubMed  Google Scholar 

  15. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83:1062–8.

    Article  CAS  PubMed  Google Scholar 

  16. Liedtke M, Medeiros BC. Plasma cell leukemia: concepts and management. Expert Rev Hematol. 2010;3:543–9.

    Article  PubMed  Google Scholar 

  17. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.

    Article  CAS  PubMed  Google Scholar 

  18. Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, et al. Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol. 2012;82:141–9.

    Article  PubMed  Google Scholar 

  19. van de Donk NWCJ, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood. 2012;120:2376–89.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau J-L, Kharfan-Dabaja MA. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant Elsevier Ltd. 2013;19:1144–51. A comprehensive description of PPCL, with practical recommendations for the management and a major focus on the role of autologous and allogeneic transplantation in this disorder, indicating that these procedures may be effective in PPCL, but a lower level than in multiple myeloma.

    Article  Google Scholar 

  21. Kraj M, Kopeć-Szlęzak J, Pogłód R, Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res. 2011;35:169–76.

    Article  CAS  PubMed  Google Scholar 

  22. Avet-Loiseau H, Roussel M, Campion L, Leleu X, Marit G, Jardel H, et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia. Nature Publishing Group 2012;26:158–9.

  23. Simeon V, Todoerti K, La Rocca F, Caivano A, Trino S, Lionetti M, et al. Molecular classification and pharmacogenetics of primary plasma cell leukemia: an initial approach toward precision medicine. Int J Mol Sci. 2015;16:17514–34. A comprehensive and updated review of molecular characteristics and pharmacogenetics of multiple myeloma and PPCL.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Chiecchio L, Protheroe RKM, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610–7.

    Article  CAS  PubMed  Google Scholar 

  25. Chiecchio L, Dagrada GP, White HE, Towsend MR, Protheroe RKM, Kan LC, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosom Cancer. 2009;48:624–36.

    Article  CAS  PubMed  Google Scholar 

  26. Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol. 2013;88:16–23. This is the first extensive genomic analysis performed in a prospective series of PPCL by means of FISH, single-nucleotide polymorphism (SNP) and gene expression profiling (GEP).

    Article  CAS  PubMed  Google Scholar 

  27. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terré C, Lafage-Pochitaloff M, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematolo. Blood. 2001;97:822–5.

    Article  CAS  PubMed  Google Scholar 

  28. Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol. 2011;22:1628–35. A large retrospective study in PPCL with relevant information about clinical outcome according to different treatments employed (conventional chemotherapy, novel agents, and stem cell transplantation).

    Article  CAS  PubMed  Google Scholar 

  29. Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res. 2009;33:259–62.

    Article  CAS  PubMed  Google Scholar 

  30. Chang H, Sloan S, Li D, Patterson B. Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet. 2005;156:150–3.

    Article  CAS  PubMed  Google Scholar 

  31. Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014;28:222–5. The first prospective clinical trial in PPCL, documenting efficacy and safety of lenalidomide in combination with dexamethasone (Rd) as frontline treatment and of lenalidomide as maintenance therapy; in this study, a significant improvement of survival in patients undergoing stem cell transplantation after Rd induction was obtained.

    Article  CAS  PubMed  Google Scholar 

  32. Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos M-V, Miguel JS. Defining and treating high-risk multiple myeloma. Leukemia. 2015;29:2119–25.

    Article  CAS  PubMed  Google Scholar 

  33. Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia. 2012;26:2398–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L, et al. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res. 2013;19:3247–58. A genomic study of PPCL revealing specific gene expression profile signatures correlated with diagnostic features and clinical outcome.

    Article  CAS  PubMed  Google Scholar 

  35. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, et al. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res. 2013;19:3130–42. The first evidence of the potential role of miRNA in the pathobiology of PPCL, with possible relationships with response to therapy and survival.

  36. Cifola I, Lionetti M, Pinatel E, Todoerti K, Mangano E, Pietrelli A, et al. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget. 2015;6:17543–58. This is the first whole-exome sequencing screen in PPCL, evidencing remarkable genetic heterogeneity of mutational patterns.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S, et al. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget. 2015;15:24205–17.

    Article  Google Scholar 

  38. Bernasconi C, Castelli G, Pagnucco G, Brusamolino E. Plasma cell leukemia: a report on 15 patients. Eur J Haematol Suppl. 1989;51:76–83.

    CAS  PubMed  Google Scholar 

  39. Costello R, Sainty D, Bouabdallah R, Fermand JP, Delmer A, Diviné M, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res. 2001;25:103–7.

    Article  CAS  PubMed  Google Scholar 

  40. Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chávez J, Tripp-Villanueva F, et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol. 2002;81:362–7.

    Article  CAS  PubMed  Google Scholar 

  41. Jiménez-Zepeda VH, Domínguez VJ. Plasma cell leukemia: a rare condition. Ann Hematol. 2006;85:263–7.

    Article  PubMed  Google Scholar 

  42. Colović M, Janković G, Suvajdzić N, Milić N, Dordević V, Janković S. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol. 2008;25:154–60.

    Article  PubMed  Google Scholar 

  43. Peijing Q, Yan X, Yafei W, Dehui Z, Zengjun L, Junyuan Q, et al. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China. Acta Haematol. 2009;121:47–51.

    Article  PubMed  Google Scholar 

  44. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125:3076–85.

    Article  CAS  PubMed  Google Scholar 

  45. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1155–66.

    Article  PubMed  Google Scholar 

  46. Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005;78:288–94.

    Article  PubMed  Google Scholar 

  47. Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 2010;95:804–9.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang M-J, Li P, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012;26:1091–7. A large registry study with comparison between autologous and allogeneic transplant procedures in PPCL, showing that (i) autologous transplantation can improve outcome of patients, although results are markedly inferior to those achieved in patients with multiple myeloma, and (ii) no significant benefit in survival occurs after allo-transplantation.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Landsburg DJ, Vogl DT, Plastaras JP, Stadtmauer EA. Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia. Clin Lymphoma Myeloma Leuk. 2014;14:e225–8.

    Article  PubMed  Google Scholar 

  50. Morris C, Iacobelli S, Gahrton G, Garderet L, Drake M, van Biezen A, et al. Has allogeneic transplantation a role in the management of plasma cell leukaemia? A study on behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT. Blood (ASH Annual Meeting Abstract). 2011. Abstract 2008. Available from: https://ash.confex.com/ash/2011/webprogram/Paper43375.html.

  51. Bensinger WI. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am. 2014;28:891–902.

    Article  PubMed  Google Scholar 

  52. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2015; Dec 29. doi: 10.1038/leu.2015.356. PMID: 26710887

  53. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Petrucci MT, Martini V, Levi A, Gallucci C, Palumbo G, Del Bianco P, et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma. 2007;48:180–2.

    Article  CAS  PubMed  Google Scholar 

  55. Bauduer F. Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma. Br J Haematol. 2002;117:996–7.

    Article  CAS  PubMed  Google Scholar 

  56. Tsiara S, Chaidos A, Kapsali H, Tzouvara E, Bourantas KL. Thalidomide administration for the treatment of resistant plasma cell leukemia. Acta Haematol. 2003;109:153–5.

    Article  PubMed  Google Scholar 

  57. Brück P, Mousset S, Bühme A, Hoelzer D, Atta J. Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment. Int J Hematol. 2007;86:66–8.

    Article  PubMed  Google Scholar 

  58. Johnston RE, Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma. 2002;43:351–4.

    Article  CAS  PubMed  Google Scholar 

  59. Wöhrer S, Ackermann J, Baldia C, Seidl S, Raderer M, Simonitsch I, et al. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone—a case report. Hematol J. 2004;5:361–3.

    Article  PubMed  Google Scholar 

  60. Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol. 2010;150:418–27.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Abe M, Yokoyama H, Tohmiya Y, Okitsu Y, Ohguchi H, Kohata K, et al. Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy. Intern Med. 2009;48:1833–5.

    Article  PubMed  Google Scholar 

  62. D’Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol. 2012;23:1499–502. A large retrospective multicenter study demonstrating the efficacy of bortezomib-based treatments in PPCL.

    Article  PubMed  Google Scholar 

  63. Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis M-C, et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am J Hematol. 2014;89:145–50. Retrospective analysis including 25 PPCL in which bortezomib-treated patients had a better survival than those receiving conventional therapies, regardless of additional autologous transplant rescue or established high risk features.

    Article  CAS  PubMed  Google Scholar 

  64. Ballanti S, Mastrodicasa E, Bolli N, Lotti F, Capolsini I, Berchicci L, et al. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nat Clin Pract Oncol. 2007;4:722–5.

    Article  PubMed  Google Scholar 

  65. Pretz J, Medeiros BC. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: no recurrence with subsequent lenalidomide therapy. Am J Hematol. 2009;84:698–9.

    Article  PubMed  Google Scholar 

  66. Benson DM, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma. 2007;48:1423–5.

    Article  CAS  PubMed  Google Scholar 

  67. Musto P, Pietrantuono G, Guariglia R, Villani O, Martorelli MC, D’Auria F, et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res. 2008;32:1637–8.

    Article  CAS  PubMed  Google Scholar 

  68. Guglielmelli T, Merlini R, Giugliano E, Saglio G. Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol. 2009;2009:867380.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Olivieri A, Attolico I, Cimminiello M, Discepoli G, Cifarelli RA. Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report. Leuk Res. 2009;33:e191–3.

    Article  CAS  PubMed  Google Scholar 

  70. Mele G, Coppi MR, Guaragna G, Spina A, Melpignano A. Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia. Leuk Res. 2016;40:30–2.

    Article  CAS  PubMed  Google Scholar 

  71. Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer. 2005;114:665–7.

    Article  PubMed  Google Scholar 

  72. Finnegan DPJ, Kettle P, Drake M, Matthews C, Alexander HD, Popat R, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma. 2006;47:1670–3.

    Article  PubMed  Google Scholar 

  73. Ataergin S, Arpaci F, Kaya A, Kaya T, Gunhan O. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol. 2006;81:987–8.

    Article  PubMed  Google Scholar 

  74. Grassinger J, Südhoff T, Andreesen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol. 2006;85:132–3.

    Article  CAS  PubMed  Google Scholar 

  75. Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D’Arena G, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007;109:2285–90.

    Article  CAS  PubMed  Google Scholar 

  76. Ali R, Beksac M, Ozkalemkas F, Ozkocaman V, Ozkan A, Ozcelik T, et al. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leuk Lymphoma. 2007;48:1426–8.

    Article  CAS  PubMed  Google Scholar 

  77. Kim SJ, Kim J, Cho Y, Seo BK, Kim BS. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol. 2007;37:382–4.

    Article  PubMed  Google Scholar 

  78. Krüger WH, Kiefer T, Schüler F, Lotze C, Busemann C, Dölken G. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation. Onkologie. 2007;30:193–5.

    Article  PubMed  Google Scholar 

  79. Capalbo S, Chiefa A, Delia M, Diomede D, Liso V. Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement. Acta Oncol (Madr). 2007;46:262–4.

    Article  Google Scholar 

  80. Al-Nawakil C, Tamburini J, Bardet V, Chapuis N, Bourry E, Roux C, et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma. 2008;49:2012–4.

    Article  CAS  PubMed  Google Scholar 

  81. Telek B, Méhes L, Batár P, Kiss A, Udvardy M. Effective PAD (bortezomib, doxorubicine, dexamethasone) treatment of a patient with plasma cell leukaemia developed after autologous stem cell transplantation. Orv Hetil. 2008;149:1957–9.

    Article  PubMed  Google Scholar 

  82. Bernardeschi P, Pirrotta MT, Montenora I, Giustarini G, Ferreri MI, Simi P, et al. Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. a case record. Leuk Res. 2010;34:e104–5.

    Article  PubMed  Google Scholar 

  83. Libby E, Candelaria-Quintana D, Moualla H, Abdul-Jaleel M, Rabinowitz I. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol. 2010;85:733–4.

    Article  PubMed  Google Scholar 

  84. Mele G, Pinna S, Melpignano A, Quarta G. Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens. Clin Ther. 2010;32:915–9.

    Article  CAS  PubMed  Google Scholar 

  85. Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy. 2005;25:1820–5.

    Article  PubMed  Google Scholar 

  86. Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res. 2008;32:1153–6.

    Article  CAS  PubMed  Google Scholar 

  87. Gozzetti A, Musto P, Defina M, D’Auria F, Papini G, Steduto T, et al. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. Br J Haematol. 2012;157:497–8.

    Article  CAS  PubMed  Google Scholar 

  88. Ueda S, Kubo M, Matsuura N, Matsunaga H, Kataoka S, Maeda T, et al. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature. Intern Med. 2013;52:1235–8.

    Article  PubMed  Google Scholar 

  89. Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. Leuk Lymphoma. 2015;56:232–5.

    Article  PubMed  Google Scholar 

  90. Tamura S, Koyama A, Shiotani C, Kurihara T, Nishikawa A, Okamoto Y, et al. Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. Intern Med. 2014;53:1171–5.

    Article  PubMed  Google Scholar 

  91. Royer B, Magrangeas F, Lioure B, Fermand J-P, Hulin C, Karlin L, et al. First large prospective study for patients with primary plasma cell leukemia: bortezomib-doxorubicin-dexamethasone/bortezomib-cyclophosphamide-dexamethasone regimens as induction before stem cell transplantation followed by consolidation with lenalidomide. Blood (ASH Annual Meeting Abstract). 2013. Abstract 761. Available from: http://www.myelomabeacon.com/tag/ash-2013-plasma-cell-leukemia/.Interim analysis of a prospective, phase 2 study with bortezomib during induction, followed by either double autologous transplantation and bortezomib plus lenalidomide as consolidation/maintenance therapy or tandem sequence of autologous followed by reduced intensity allogeneic transplantation, in younger patients with newly diagnosed PPCL.

  92. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–52.

    Article  PubMed  Google Scholar 

  93. Talamo G, Dolloff NG, Sharma K, Zhu J, Malysz J. Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents. Rare Tumors. 2012;4:e39.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Iriuchishima H, Ozaki S, Konishi J, Matsumoto M, Murayama K, Nakamura F, et al. Primary plasma cell leukemia in the era of novel agents: a multicenter study of the Japanese Society of Myeloma. Acta Haematol. 2016;135:113–21.

    Article  CAS  PubMed  Google Scholar 

  95. Musto P. Novel agents for the treatment of primary plasma-cell leukemia: lights and shadows. Acta Haematol. 2016;135:110–2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy

    Pellegrino Musto MD

  2. Laboratory of Pre-clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy

    Vittorio Simeon PhD & Katia Todoerti PhD

  3. Department of Oncology and Hemato-oncology, University of Milano, Hematology, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy

    Antonino Neri MD, PhD

Authors
  1. Pellegrino Musto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vittorio Simeon PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katia Todoerti PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonino Neri MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pellegrino Musto MD.

Ethics declarations

Conflict of Interest

Pellegrino Musto has received honoraria from Celgene, Janssen, Bristol-Myers Squibb, Sanofi, and Amgen for development of educational presentations including service on speakers’ bureaus.

The other authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Leukemia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Musto, P., Simeon, V., Todoerti, K. et al. Primary Plasma Cell Leukemia: Identity Card 2016. Curr. Treat. Options in Oncol. 17, 19 (2016). https://doi.org/10.1007/s11864-016-0392-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-016-0392-6

Keywords

Search

Navigation